Trial Profile
A retrospective study to compare intravenous vernakalant and electrical cardioversion in recent-onset atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2017
Price :
$35
*
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 01 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 30 Aug 2017 Primary endpoint has been met (Length of hospital stay), according to a Cardiome Pharma media release.